Polycythemia vera: diagnosis and treatment 2002

References

• Osler W Chronic cyanosis with polycythemia and enlarged spleen: a new clinical entity. 44,187–201 (1903).
   Google Scholar
• ••First description and classification of thepolycythemia.
   Google Scholar
• Lawrence JH, Berlin NI. Relative polycythemia-the polycythemia of stress. J. Biol. Med. 24, 498–505 (1952).
   Google Scholar
• •The original description of relative (stress) polycythemia.
   Google Scholar
• Lawrence JH, Berlin NI, Huff RL. The nature and treatment of polycythemia. Medicine 33,323–388 (1953).
   Google Scholar
• ••Comprehensive review of the polycythemias and the first report of the life expectancy in patients treated with 3213.
   Google Scholar
• Calabresi P, Meyer OO. Polycythemia I. Clinical and laboratory manifestations. Ann. Int. Med. 50,1182-1202 (1959): Polycythemia II. Course and Therapy 1203–1216 (1959).
   Google Scholar
• Wiseman BK, Rohn R, Bouronde BA, Myers WG. The treatment of polycythemia Vera with radioactive phosphorus. Ann. Int. Med. 34,311–330 (1951).
   PubMedGoogle Scholar
• Szur L, Lewis SM, Goolden AWG. Polycythemia vera and its treatment with radioactive phosphorus. Quart. J. Med. New Series XXVIII, 397–426 (1959).
   Google Scholar
• Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med. Scand. 172,513–523 (1962).
   PubMed Web of Science ®Google Scholar
• ••The often cited source of the lifeexpectancy in untreated and treated patients.
   Google Scholar
• Videbaek A. Polycythemia vera — course and prognosis. Acta Med. Scand. 138,179–187 (1950).
   PubMedGoogle Scholar
• Rozman C, Giralt M, Feliu E, Rubio D, Cortes M-T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67, 2658–2663 (1991).
   Google Scholar
• •The report of the life expectancy in a single nation (Spain).
   Google Scholar
• Osgood EE Contrasting Incidence of Acute monocytic and granulocytic leukemias in P32 treated patients with polycythemia vera and chronic lymphocytic leukemia. J. Lab. Clin. Med 64,560–573 (1964).
   Google Scholar
• Modan B, Lilienfeld AM. Polycythemia vera and leukemia — the role of radiationtreatment. Medicine 44,305–344 (1965).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review particularly of theeffect of radiation treatment.
   Google Scholar
• Berk PD, Goldberg JD, Donovon PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic Recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin. Hem. 23,132–143 (1996).
   Google Scholar
• ••Therapeutic recommendations derivedfrom a randomized trial.
   Google Scholar
• Najean Y, Rain J-D for the French Polycythemia Vera Study Group.Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90, 3370–3377 (1997).
   Google Scholar
• Najean Y, Rain J-D for the French Polycythemia Vera Study Group.Treatment of Polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood89, 2319–2327 (1997).
   Google Scholar
• Perkins J, Israels MCG, Wilkinson JF. Polycythemia vera: clinical studies on a series of 127 patients managed without radiation therapy. Quart. J. Med New Series )(XXIII, 499–518 (1964).
   Google Scholar
• Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin. Hemat. 34,17–23 (1997).
   PubMed Web of Science ®Google Scholar
• Berlin NI. The diagnosis and classification of the polycythemias. Semin. Hemat. 12, 339–351 (1976).
   Google Scholar
• ••The frequently cited diagnostic criteria.
   Google Scholar
• Berlin NI. Classification of the polycythemias and initial clinical features in polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders. Wasserman LR, Berk PD, Berlin NI (Eds) WB Saunders, PA, USA 22–30 (1995).
   Google Scholar
• Fruchtman S, Wasserman LR Therapeutic Recommendations for polycythemia vera. In Polycythemia Vera and the Myeloproliferative Disorders. Wasserman LR, Berk PD, Berlin NI (Eds.), WB Saunders Company, PA, USA, 337–349 (1995).
   Google Scholar
• Berlin NI, Lawrence JH, Gartland J. Blood volume in polycythemia as determined by labeled red cells. Am. J. Med 9,747–751 (1950).
   Google Scholar
• •First report of the use of isotopically labeled red cells and the occurrence of relative polycythemia.
   Google Scholar
• Berlin NI, Lewis SM. Measurement of total RBC volume relative to lean body mass for diagnosis of polycythemia. Am. J. Chn. Path. 114,922–926 (2000).
   PubMedGoogle Scholar
• •Report the solution of the problem of how to interpret a blood volume in the obese.
   Google Scholar
• Pearson TC, Messinezy M. The diagnostic criteria of polycythemia rubra vera. Leuk. Lymph. 22\(Suppl. 1), 87–93 (1996).
   Google Scholar
• Michiels JJ, Juvonen ER Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Sem. Thromb. Hemo. 23,339–347 (1997).
   PubMed Web of Science ®Google Scholar
• Tefferi A. Diagnosing Polycythemia vera: a paradigm shift. Mayo Chn. Proc. 74,159–162 (1999).
   PubMedGoogle Scholar
• •New algorithm for the differential diagnosis of an elevated hematocrit.
   Google Scholar
• Djulbegovic B, Hozo I. Computer program for the diagnosis and treatment of polycythemia vera. MD computing 16,83–89 (1999).
   PubMedGoogle Scholar
• Donovan P, Kaplan ME, Goldberg JD et id Treatment of polycythemia vera with hydroxyurea. Am. J. Hemat. 17, 329–334 (1984).
   PubMed Web of Science ®Google Scholar
• Silver RT. Recombinant interferon-a for treatment of polycythemia Vera. Lancet 2, 403 (1988).
   PubMedGoogle Scholar
• ••First report of the use of interferon inpolycythemia vera.
   Google Scholar
• Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia in polycythemia vera and allied disorders: prospective study of the efficacy and leukemogenicity with therapeutic implications. Eur. j Haemat. 52,134-139 (1994).
   Google Scholar
• ••First report of the leukemogenicity ofhydroxyurea.
   Google Scholar
• Tatarsky I, Sharon R Management of polycythemia vera with hydroxyurea. Semin. Hematot 34,24–28 (1997).
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano Studio Polycitemia. Low-dose aspirin in polycythemia vera: a pilot study. Br. J. Haemat. 97,453–456 (1997).
   PubMedGoogle Scholar
• Najean Y, Rain J-D. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin. Hematol. 34,6-16 (1997).
   Google Scholar
• ••A comprehensive report of the effects ofphlebotomy alone.
   Google Scholar
• Berk PD, Goldberg JD, Silverstein MN et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl. Med. 304, 441–447 (1981).
   PubMed Web of Science ®Google Scholar
• •The report that chlorambucil is a leukemogen.
   Google Scholar
• Balan KK, Crtitchley M. Outcome of 259 patients with primary proliferative polycythemia (PPP) and idiopathic thrombocythemia (M treated in a regional nuclear medicine department with phosphorus-32-a 15 year review. Br. J. Radial. 70,1169-1173 (1997).
   Google Scholar
• Abbatt JD, Chaplin H, Darte JMM, Pitney WR. Treatment of polycythemia vera with radiophosphorus. Quart. J. Med. New Series XXIII 89,91–104 (1954).
   Google Scholar
• Brandt L, Anderson H. Survival and risk of leukemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus: are safer drugs available. Eur. I Haematol. 54,21–26 (1995).
   PubMed Web of Science ®Google Scholar
• •A contemporary paper advocating the use of 32P
   Google Scholar
• Petti MC, Spadea A, Avvisat G et al. Polycythemia vera treated with pipobroman as single agent:low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–1991) Leukemia 12, 869–874 (1998).
   Google Scholar
• Passamonti F, Brusamolino E, T nzzarino M et al. Efficacy of pipobroman in the treatment of polycythmia vera: long-term results in 163 patients. Hematologica 10, 1011–1018 (2000).
   Google Scholar
• Haanen C, Marthe G, Hayat M. Treatment of polycythemia vera by radiophosphorus or busulphan: a randomized study. Br. J. Cancer 44,75–80 (1981).
   Google Scholar
• •A randomized trial of the use of busulfan.
   Google Scholar
• Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythemia by venesection and low-dose busulphan. Retrospective study from one centre. Br. J. Haemat. 61, 657–666 (1985).
   Google Scholar
• Streieff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 99, 1111 1149 (2002).
   Google Scholar
• ••A survey of the practice patterns of theAmerican hematologists.
   Google Scholar
• Silver RT. Interferon alpha: Effects of long treatment with for polycythemia vera. Semin. Hemata 34,40–50 (1997).
   PubMedGoogle Scholar
• Taylor PC, Dolan G, Ng JP. Efficacy of recombinant interferon-a (rIFN-a) in polycythemia vera: a study of 17 patients and an analysis of published data. Br. J. Haemat. 92,55-59 (1996).
   Google Scholar
• Klippel S, Strunck E, Temerinac S et al. Quantification of PRV-1 expression, a molecular marker for the diagnosis of polycythemia vera American Society of Hematology 43rd Annual Meeting December (2001) (Abstract 1965).
   Google Scholar
• Deeg HJ, Platzbecker U, Sale GE et aZ Allogeneic stem cell transplantation for myelofibrosis. American Society of Hematology 43rd Annual Meeting, December (2001) (Abstract 3557).
   Google Scholar
• ••A new approach to the treatment ofmyelosclerosis.
   Google Scholar
• Najean Y, Dresch C, Rain J-D, Chomienne C. Radioisotope investigations for the diagnosis and follow-up of polycythemic patients. In: Polycythemia Vera and the Myeloproliferative Disorders. Wasserman LR, Berk PD, Berlin NI (Eds.), WB Saunders Company, PA, USA, 79–90 (1995).
   Google Scholar
• Molitemo AR,Hankins WD,Spivak JL Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl. J. Med. 338, 572–580 (1998).
   PubMedGoogle Scholar
• •Anew marker for the differential diagnosis of an elevated hemocrit.
   Google Scholar